FDA Approves New Fast-Acting Insulin

The FDA has approved Fiasp (insulin aspart injection) 100 Units/mL, a fast-acting mealtime insulin indicated for use in adults with type 1 and type 2 diabetes.

Fiasp is a new formulation of NovoLog, now including niacinamide (vitamin B3) which helps to increase the speed of insulin absorption.

The approval of Fiasp was based upon the results of a Phase 3a clinical development program in which adults with type 1 and type 2 diabetes experienced reduction in A1c when using the drug.

Common adverse events include nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, and back pain.

—Michael Potts

Reference:

Novo Nordisk receives FDA approval for Fiasp®, a new fast-acting mealtime insulin [press release]. Plainsboro, New Jersey. September 29, 2017. http://press.novonordisk-us.com/2017-09-29-Novo-Nordisk-Receives-FDA-Approval-for-Fiasp-R-a-New-Fast-Acting-Mealtime-Insulin.